EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis

Axel Dignass iD, Claire Ainsworth, Susanne Hartz iD, Niels Dunnewind, Isabel Redondo, Christophe Sapin, Sonja Kroep, Nicholas Halfpenny, Emanuele Arcà, Sami Hoque

Advances in Therapy · 2024

DOI: 10.1007/s12325-024-03003-8 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Advances in Therapy, 2024. Verfasst von Axel Dignass und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, Oncology and Pneumology, Markus Hospital, Frankfurt, Germany. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The preparation of the manuscript was funded by Eli Lilly and Company..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: This study aimed to compare the efficacy and safety of biologics and small molecules for treatment of adults with moderately-to-severely active ulcerative colitis (UC). METHODS: A systematic literature review was conducted to identify randomised controlled trials evaluating approved and emerging targeted therapies for patients with UC. A Bayesian network meta-analysis (NMA) approach was applied. Outcomes assessed included clinical response and remission, endoscopic mucosal healing, and safety. RESULTS: Thirty studies were included in the NMA following a feasibility assessment comparing approved induction dosing regimens and 22 studies comparing approved maintenance dosing regimens. In the biologic/Janus kinase inhibitor (JAKi)-naïve population, induction studies showed similar clinical response and remission rates across most interventions, with upadacitinib demonstrating significant improvements versus most other interventions. For maintenance studies, mirikizumab demonstrated significant improvements in clinical response and remission versus most other interventions. In the biologic/JAKi-experienced population, no significant differences were observed between most interventions in induction studies, except for significantly improved clinical response and remission for mirikizumab versus adalimumab, and upadacitinib demonstrated significant improvement versus all other interventions. Few differences between active treatments were observed in maintenance studies. In both populations, all active interventions had similar efficacy in terms of endoscopic mucosal healing in both induction and maintenance studies. Regardless of prior treatment exposure, similar rates of serious adverse events were seen across all active interventions in the induction period. CONCLUSION: Among the available interventions, owing to its favourable efficacy and safety profile, mirikizumab has a relevant role in the long-term treatment of UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansAdalimumabBayes TheoremBiological ProductsGastrointestinal AgentsJanus Kinase InhibitorsRandomized Controlled Trials as TopicRemission InductionSeverity of Illness IndexTreatment OutcomeHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

Advanced therapiesBiologicsComparative efficacyIL-23 inhibitorsMirikizumabSmall moleculesUlcerative colitis

Substanzen

AdalimumabBiological ProductsGastrointestinal AgentsJanus Kinase InhibitorsupadacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology, Oncology and Pneumology, Markus Hospital, Frankfurt, Germany.
  • OPEN Health HEOR & Market Access, Manchester, UK.
  • Eli Lilly and Company, Indianapolis, IN, USA. hartz_susanne@lilly.com.
  • Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, Bracknell, RG12 1PU, UK. hartz_susanne@lilly.com.
  • OPEN Health HEOR & Market Access, Rotterdam, Netherlands.
  • Eli Lilly and Company, Indianapolis, IN, USA.

ORCID-Profile: Axel Dignass, Susanne Hartz

Förderung

  • The preparation of the manuscript was funded by Eli Lilly and Company.

Zitieren

APA

Dignass, A., Ainsworth, C., Hartz, S., Dunnewind, N., Redondo, I., Sapin, C., Kroep, S., Halfpenny, N., Arcà, E., & Hoque, S. (2024). Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis. Advances in Therapy. https://doi.org/10.1007/s12325-024-03003-8

Vancouver

Dignass A, Ainsworth C, Hartz S, Dunnewind N, Redondo I, Sapin C, et al. Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis. Advances in Therapy. 2024. doi:10.1007/s12325-024-03003-8

BibTeX
@article{Dignass2024,
  author = {Dignass, Axel and Ainsworth, Claire and Hartz, Susanne and Dunnewind, Niels and Redondo, Isabel and Sapin, Christophe and Kroep, Sonja and Halfpenny, Nicholas and Arcà, Emanuele and Hoque, Sami},
  title = {Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis},
  journal = {Advances in Therapy},
  year = {2024},
  doi = {10.1007/s12325-024-03003-8}
}
Kostenlos starten →